{"id":295739,"date":"2019-10-02T22:30:26","date_gmt":"2019-10-03T05:30:26","guid":{"rendered":"https:\/\/nai500.com\/blog\/2019\/10\/iaso-and-innovent-approved-to-start-trial\/"},"modified":"2019-10-03T00:28:20","modified_gmt":"2019-10-03T07:28:20","slug":"%e9%a6%b4%e9%b9%bf%e9%86%ab%e7%99%82%e5%92%8c%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e7%8d%b2%e5%87%86%e5%95%9f%e5%8b%95car-t","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hant\/blog\/2019\/10\/%e9%a6%b4%e9%b9%bf%e9%86%ab%e7%99%82%e5%92%8c%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e7%8d%b2%e5%87%86%e5%95%9f%e5%8b%95car-t\/","title":{"rendered":"\u99b4\u9e7f\u91ab\u7642\u548c\u4fe1\u9054\u751f\u7269\u7372\u51c6\u555f\u52d5CAR-T\u514d\u75ab\u7642\u6cd5\u7684\u8a66\u9a57"},"content":{"rendered":"<p>\u5357\u4eac\u99b4\u9e7f\u91ab\u7642\u6280\u8853\u6709\u9650\u516c\u53f8\u53ca\u5176\u5408\u4f5c\u5925\u4f34\u8607\u5dde\u4fe1\u9054\u751f\u7269\u5ba3\u4f48\uff0c\u4ed6\u5011\u5171\u540c\u958b\u767c\u7684CAR-T\u7642\u6cd5\u88ab\u6279\u51c6\u5728\u4e2d\u570b\u958b\u59cb\u5c0d\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u9032\u884cIb \/ II\u671f\u8a66\u9a57\u3002\u99b4\u9e7f\u91ab\u7642\u8868\u793a\uff0cCT103A\u662f\u70ba\u5728CAR-T\u6cbb\u7642\u5f8c\u5fa9\u767c\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u8a2d\u8a08\u7684\u3002\u99b4\u9e7f\u91ab\u7642\u9084\u8868\u793a\uff0c\u5728\u4e00\u9805\u4e2d\u570bIIT\u7814\u7a76\u4e2d\uff0c\u6bcf8\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\u67097\u4f8b\u5be6\u73fe\u4e86\u5f88\u597d\u7684\u5c40\u90e8\u53cd\u61c9\u6216\u66f4\u597d\u7642\u6548\u3002<\/p>\n<p>\u82f1\u6587\u4f86\u6e90\uff1aChina Biotoday<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Biotherapeutics of Nanjing and its partner, Suzhou Innovent Biologics, announced that their jointly developed CAR-T therapy was approved to start a Phase Ib\/II trial in China in patients with relapsed\/refractory multiple myeloma. IASO said CT103A was designed for rr\/mm patients who have relapsed after CAR-T treatment. Because repeat CAR-T rounds are not effective, CT103A was developed using a lentiviral vector containing a CAR structure. IASO said 7 out of 8 evaluable patients in a China IIT study achieved very good partial response or better.<\/p>\n","protected":false},"author":9,"featured_media":295733,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[426],"tags":[563],"class_list":["post-295739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hant","tag--zh-hant","sectors-life-science-zh-hant","locations-china-zh-hant"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/295739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=295739"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/295739\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media\/295733"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=295739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=295739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=295739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}